Curated News
By: NewsRamp Editorial Staff
February 20, 2026

BioStem Technologies to Present at Prestigious TD Cowen Healthcare Conference

View History of this news story on GitHub
Original Source

TLDR

  • BioStem Technologies gains investor exposure by presenting at the TD Cowen Healthcare Conference, potentially boosting its market position and stock value.
  • BioStem Technologies will present at the TD Cowen Healthcare Conference on March 2, 2026, at 3:50 pm ET, with a webcast available on their investor site.
  • BioStem's presentation highlights their regenerative therapies, which aim to improve advanced wound care and enhance patient recovery outcomes.
  • BioStem Technologies uses perinatal tissue and its BioRetain method to create innovative allografts for regenerative medicine.

Impact - Why it Matters

This presentation represents a significant milestone for BioStem Technologies as it seeks to expand its influence in the regenerative medicine sector. For investors, this provides crucial insight into the company's strategic direction, technological advancements, and market positioning within the competitive wound care industry. For patients and healthcare providers, BioStem's continued progress in perinatal tissue-derived therapies could translate to more effective treatment options for chronic wounds and tissue regeneration, potentially improving recovery outcomes and quality of life. The company's participation in such a prominent industry conference signals growing recognition of their innovative approach to maintaining growth factors and preserving tissue structure through their proprietary BioRetain® method, which could accelerate adoption of their products across healthcare systems.

Summary

BioStem Technologies, Inc., a leading MedTech company specializing in perinatal tissue-derived products for advanced wound care, has announced that its management team will present at the prestigious 46th Annual TD Cowen Healthcare Conference in Boston. The presentation, scheduled for March 2, 2026, at 3:50 pm ET, represents a significant opportunity for the company to showcase its innovative regenerative therapies to investors and industry leaders. BioStem's portfolio includes notable brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and the Neox® and Clarix® product lines, all developed using their proprietary BioRetain® processing method that preserves growth factors and tissue structure.

The company's commitment to quality is underscored by its accreditation from the American Association of Tissue Banks and compliance with current Good Tissue Practices and Good Manufacturing Processes. Interested parties can access live and archived webcasts of the presentation through the investors section of the company's website at ir.biostemtechnologies.com, providing transparency and engagement opportunities for stakeholders. This announcement was distributed through PRISM MediaWire, a trusted press release distribution service, highlighting the professional dissemination of this corporate news.

For those following BioStem's developments, the company encourages engagement through multiple channels including their website at biostemtechnologies.com, social media platforms like X and LinkedIn, and their email distribution list available HERE. The presentation at this major healthcare conference positions BioStem Technologies to potentially attract new investment and partnerships as it continues to advance its mission of manufacturing products that change lives through regenerative medicine. Additional company information and updates relating to $BMES are available through their dedicated newsroom at https://tinyurl.com/bsemnewsroom.

Source Statement

This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, BioStem Technologies to Present at Prestigious TD Cowen Healthcare Conference

blockchain registration record for this content.